Edwards Lifesciences Corporation Share Price
Equities
EW
US28176E1082
Advanced Medical Equipment & Technology
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 73.42 USD | -0.98% |
|
-0.66% | -0.82% |
| 01-10 | Pulse Biosciences Names Paul LaViolette CEO | MT |
| 01-10 | Pulse Biosciences, Inc. Appoints Paul A. LaViolette as Chief Executive Officer | CI |
| Capitalization | 43.3B 42.31B 39.73B 35.5B 62.52B 3,731B 70.48B 487B 181B 1,534B 162B 159B 6,835B | P/E ratio 2024 * |
31.8x | P/E ratio 2025 * | 30.7x |
|---|---|---|---|---|---|
| Enterprise value | 39.61B 38.7B 36.34B 32.47B 57.18B 3,412B 64.47B 445B 165B 1,403B 149B 145B 6,252B | EV / Sales 2024 * |
6.71x | EV / Sales 2025 * | 6.79x |
| Free-Float |
89.32% | Yield 2024 * |
-
| Yield 2025 * | - |
More valuation ratios
* Estimated data
More news
Last Transcript: Edwards Lifesciences Corporation
More recommendations
More press releases
More news
| 1 day | -0.98% | ||
| 1 week | -0.66% | ||
| Current month | -0.82% | ||
| 1 month | -0.53% | ||
| 3 months | +7.76% | ||
| 6 months | -20.93% | ||
| Current year | -0.82% |
1 week
72.89
74.74
1 month
71.9776.23
Current year
71.9774.74
1 year
58.9396.12
3 years
58.93131.10
5 years
51.51131.73
10 years
20.46131.73
| Director | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 57 | 10/05/2023 | |
Scott Ullem
DFI | Director of Finance/CFO | 58 | 31/12/2013 |
Todd Brinton
CTO | Chief Tech/Sci/R&D Officer | - | 31/01/2019 |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chairman | 68 | 06/05/2024 | |
Kieran Gallahue
BRD | Director/Board Member | 61 | 09/02/2015 |
| Director/Board Member | 57 | 10/05/2023 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 2.46% | 46 M€ | +1.29% | - | |
| 2.34% | 30 M€ | -0.48% | - | |
| 1.17% | 24 M€ | -0.03% | - |
| Change | 5d. change | 1-year change | 3-years change | Capi. ($) | ||
|---|---|---|---|---|---|---|
| -0.98% | -0.66% | -2.29% | -39.79% | 43.3B | ||
| -0.48% | +1.93% | -0.68% | -12.60% | 207B | ||
| +0.63% | +2.27% | +51.11% | +66.90% | 195B | ||
| -1.27% | +0.10% | +3.12% | -23.01% | 170B | ||
| -1.12% | +4.62% | +59.17% | +118.62% | 140B | ||
| +0.82% | +0.55% | -1.57% | -16.75% | 58.97B | ||
| +0.34% | +1.31% | +6.01% | -6.25% | 39.26B | ||
| -1.74% | +5.27% | +11.16% | - | 38.72B | ||
| -2.23% | -5.20% | -17.56% | -27.59% | 38.1B | ||
| -1.00% | +0.93% | +31.44% | -1.91% | 34.34B | ||
| Average | -0.70% | +1.64% | +13.99% | +6.40% | 96.48B | |
| Weighted average by Cap. | -0.54% | +2.35% | +20.23% | +20.56% |
| 2024 * | 2025 * | |
|---|---|---|
| Net sales | 5.91B 5.77B 5.42B 4.84B 8.53B 509B 9.61B 66.36B 24.62B 209B 22.16B 21.7B 932B | 5.85B 5.71B 5.36B 4.79B 8.44B 504B 9.52B 65.69B 24.37B 207B 21.93B 21.48B 923B |
| Net income | 1.38B 1.35B 1.27B 1.13B 2B 119B 2.25B 15.53B 5.76B 48.96B 5.19B 5.08B 218B | 1.41B 1.38B 1.29B 1.16B 2.03B 121B 2.29B 15.83B 5.87B 49.91B 5.29B 5.18B 222B |
| Net Debt | -3.69B -3.61B -3.39B -3.03B -5.33B -318B -6.01B -41.49B -15.39B -131B -13.85B -13.56B -583B | -3.61B -3.52B -3.31B -2.96B -5.21B -311B -5.87B -40.51B -15.03B -128B -13.53B -13.24B -569B |
More financial data
* Estimated data
Employees
19,800
Calendar
14/01/2025
- JP Morgan Healthcare Conference
| Date | Price | Change | Volume |
|---|---|---|---|
| 10/01/25 | 73.42 $ | -0.98% | 3,473,379 |
| 08/01/25 | 74.15 $ | +0.69% | 3,447,118 |
| 07/01/25 | 73.64 $ | +0.14% | 3,093,941 |
| 06/01/25 | 73.54 $ | -0.50% | 4,102,477 |
Delayed Quote Nyse, January 10, 2025 at 09:00 pm
More quotes
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
33
Last Close Price
73.42USD
Average target price
79.57USD
Spread / Average Target
+8.38%
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- EW Stock
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition